All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
JAK inhibitors
JAK inhibitors
Janus kinase (JAK) proteins promote survival and proliferation of cells by activation of the STAT signaling pathway and are induced by hematopoietic cytokine and growth factor receptor activation. Constitutive activation of JAKs is seen in most patients with MPN and JAK inhibitors, such as ruxolitinib, filgotinib, and tofacitinib, have shown clinical activity in these patients.
Save to your areas of interest